Korro Bio to Begin RNA-Editing Trial in Alpha-1...
CMN Clinical
Dec. 4, 2024
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Amber Bio
Company Type: Therapeutics
Main focus: Development of therapeutics based on a new gene-editing modality
Company stage: Pre-clinical
Diseases: Undisclosed
Genome-editing tool: CRISPR-based RNA-writing technology
Funding stage: Seed
Location: Cambridge, Massachusetts, United States
Website: https://www.amber.bio/
Pipeline:
Partners:
Amber Bio is a pre-clinical stage company that is investigating new ways to address genetic conditions by leveraging its novel “multi-kilobase-scale” RNA-writing technology. The technology exploits some of the newest findings within CRISPR biology to reach previously undruggable patient populations, by editing thousands of diverse mutations across patients with a single product.
